Large-cap Consumer Discretionary company Kenvue has moved -2.4% so far today on a volume of 20,863,452, compared to its average of 23,400,393. In contrast, the S&P 500 index moved -1.0%.
Kenvue trades -13.32% away from its average analyst target price of $24.17 per share. The 12 analysts following the stock have set target prices ranging from $20.0 to $27.0, and on average have given Kenvue a rating of buy.
If you are considering an investment in KVUE, you'll want to know the following:
-
Kenvue has moved -20.2% over the last year, and the S&P 500 logged a change of 22.9%
-
Based on its trailing earnings per share of 0.57, Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 36.8 while the S&P 500 average is 15.97
-
KVUE has a forward P/E ratio of 16.5 based on its forward 12 month price to earnings (EPS) of $1.27 per share
-
The company has a price to earnings growth (PEG) ratio of 11.51 — a number near or below 1 signifying that Kenvue is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.68 compared to its sector average of 4.24
-
Kenvue Inc. operates as a consumer health company worldwide.
-
Based in Skillman, the company has 22,200 full time employees and a market cap of $40.12 Billion. Kenvue currently returns an annual dividend yield of 0.9%.